Sunita D Nasta, MD

She/Her/Hers
Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Headshot of Sunita D Nasta, MD
Penn Medicine Provider

About me

  • Chair, Clinical Trials Review Monitoring Committee
  • Committee Chair, Penn Institutional Review Board
  • Section Chief, Lymphoma, Hematology-Oncology
  • Professor of Clinical Medicine (Hematology-Oncology)

Dr Sunita Nasta has been working for a cure for lymphoma for over 20 years at the University of Pennsylvania Perelman School of Medicine. Patients and their families are the core of the battle. Working one patient at a time, she has taken her findings from the bedside back to her collaborators in the labs. From personalized diagnostics which find the specific mutations that drive lymphoma to the deficits that prevents the immune system from reacting to cancer to the challenges of survivors, she has seen the landscape change. While the war is not won, she knows that  each battle fought is one step closer. She is also a regional/national expert in the management of patients with Castleman disorder and Histiocytic disorders.

My education and training

  • Medical School: Virginia Commonwealth University
  • Residency: Baylor College of Medicine
  • Residency: Baylor College of Medicine - Ben Taub General Hospital
  • Fellowship: Baylor College of Medicine
  • Fellowship: University Texas Health Science Center San Antonio
  • Fellowship: University of Texas - MD Anderson Cancer Center

Spoken languages

English
English

Reviews

Average Rating

1206 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
she sincere, friendly, empathetic, extremely knowledgeable and just wonderful!
Anonymous
May 2026
she is outstanding knowledge and making the next steps quickly
Anonymous
May 2026
she has an excellent bed side manner.
Anonymous
May 2026
dr nasta knows what she's doing

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Nasta is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Marco Ruella, M.D., Luca Paruzzo, M.D., Emeline R. Chong, B.A., Elise A. Chong, M.D., Daniel J. Landsburg, M.D., Sunita D. Nasta, M.D., Pooja Devi, M.D., +12, and Stephen J. Schuster, M.D. Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas , N Engl J Med, 394(2): 2026,2440-2448


Fang CY, MacFarlane AW 4th, Fung HCH, Khan N, Barta SK, Hasler JS, Ballard HJ, Landsburg DJ, Nasta SD, Schuster SJ, Khanal R, Fisher RI, Cohen AD, Svoboda J, Campbell KS Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance. , Cancer Med., 15(5): 2026,e71903


Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfò L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. , Blood Adv., 10(7): 2026,2441-2451


Thomas CJ, Myers CS, Chung J, Landsburg D, Nasta SD, Svoboda J, Chong EA, Schuster SJ, Carter J, Cook M, Tomasulo E, Elghawy O, LaRiviere M, Hubbeling H, Plastaras JP, Rook AH, Villasenor-Park J, Ruella M, Kim E, Barta SK. Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden. , Blood Neoplasia. 2026 Apr 25;3(3):., 3(3): 2026,100239


Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT. Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma. , Leukemia, 40(3): 2026,694-697


Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD. Methotrexate-associated Peripheral Neuropathy on 18 F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis. , Clin Nucl Med., 51(2): 2026,e144-e146


Jiang C, Hoover T, Baron J, Han X, Li B, Gao Y, Kim M, Hubbeling H, Chong EA, Carter J, Svoboda J, Schuster SJ, Landsburg DJ, Nasta SD, Plastaras J, LaRiviere M. Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma. , Int J Part Ther., 19: 2026,101304


Carrie Thompson 1, Marek Trněný 2, Franck Morschhauser 3, Gilles Salles 4, Patrick M Reagan 5, Mark Hertzberg 6, Huilai Zhang 7, Catherine Thieblemont 8, Bei Hu 9, Gustavo Fonseca 10, Won Seog Kim 11, Maurizio Martelli 12, Amitkumar Mehta 13, Avrita Singh 14, Mark Yan 15, Jamie Hirata 14, Matthew Sugidono 14, Calvin Lee 14, Jeff P Sharman 16, Neha Mehta-Shah 17, Christopher R Flowers 18, Hervé Tilly 19, Neil Chua 20, René-Olivier Casasnovas 21, Fiona Miall 22, Tae Min Kim 23, Xavier Cheng-Hong Tsai 24, Sunita Nasta 25, Seung Tae Lee 26, Jonathan W Friedberg 5 PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study , Blood, 147(3): 2026,254-265


Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. , JAMA Dermatol., 161(6): 2025 ,e250251


Potluri VS, Zhang S, Schaubel DE, Shaikhouni S, Blumberg EA, Nasta SD, Bloom RD, Cruz-Peralta M, Mehta RB, Lavu NR, Getachew B, Tandukar S, Reese PP, Puttarajappa CM. The Association of Epstein-Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation : A Retrospective Cohort Study , Ann Intern Med., 178(2): 2025 ,157-166